These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 16638371

  • 1. A review of rituximab in cutaneous medicine.
    Scheinfeld N.
    Dermatol Online J; 2006 Jan 27; 12(1):3. PubMed ID: 16638371
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A, Keating MJ, Stasi R, Bradstock K.
    Anticancer Drugs; 2002 Nov 27; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [Abstract] [Full Text] [Related]

  • 3. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V, Mydlarski PR.
    Skin Therapy Lett; 2007 Nov 27; 12(6):6-9. PubMed ID: 17762903
    [Abstract] [Full Text] [Related]

  • 4. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
    Arin MJ, Hunzelmann N.
    Eur J Dermatol; 2005 Nov 27; 15(4):224-30. PubMed ID: 16048747
    [Abstract] [Full Text] [Related]

  • 5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 27; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ, Wolverton SE.
    J Drugs Dermatol; 2007 Sep 27; 6(9):883-9. PubMed ID: 17941359
    [Abstract] [Full Text] [Related]

  • 7. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan 27; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 8. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R.
    Cancer; 2000 Oct 15; 89(8):1835-44. PubMed ID: 11042581
    [Abstract] [Full Text] [Related]

  • 9. Rituximab: applications in dermatology.
    Fatourechi MM, el-Azhary RA, Gibson LE.
    Int J Dermatol; 2006 Oct 15; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
    [Abstract] [Full Text] [Related]

  • 10. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR.
    Int Immunopharmacol; 2009 Jan 15; 9(1):10-25. PubMed ID: 19000786
    [Abstract] [Full Text] [Related]

  • 11. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C, Castillo J.
    Curr Opin Mol Ther; 2009 Apr 15; 11(2):200-7. PubMed ID: 19330725
    [Abstract] [Full Text] [Related]

  • 12. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B, Santos ES.
    Expert Rev Anticancer Ther; 2007 Mar 15; 7(3):257-73. PubMed ID: 17338647
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M.
    Clin Exp Dermatol; 2006 Jul 15; 31(4):503-8. PubMed ID: 16716150
    [Abstract] [Full Text] [Related]

  • 14. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
    Mitrović Z, Aurer I.
    Lijec Vjesn; 2006 Jul 15; 128(1-2):36-42. PubMed ID: 16640226
    [Abstract] [Full Text] [Related]

  • 15. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.
    Dermatology; 2007 Jul 15; 214(4):310-8. PubMed ID: 17460402
    [Abstract] [Full Text] [Related]

  • 16. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
    Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-López A, Benyunes M, Grobman B, Dillman RO.
    Semin Oncol; 2000 Dec 15; 27(6 Suppl 12):53-61. PubMed ID: 11226001
    [Abstract] [Full Text] [Related]

  • 17. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.
    Br J Dermatol; 2005 Mar 15; 152(3):541-4. PubMed ID: 15787825
    [Abstract] [Full Text] [Related]

  • 18. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ, Entezari V.
    Clin Appl Thromb Hemost; 2006 Oct 15; 12(4):489-92. PubMed ID: 17000895
    [Abstract] [Full Text] [Related]

  • 19. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.
    Schadlow MB, Anhalt GJ, Sinha AA.
    J Drugs Dermatol; 2003 Oct 15; 2(5):564-7. PubMed ID: 14558407
    [Abstract] [Full Text] [Related]

  • 20. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
    Prodanovic EM, Korman NJ.
    J Dermatolog Treat; 2008 Oct 15; 19(6):1-3. PubMed ID: 18720187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.